4Hayeck T J, Kong C Y, Spechler S J, et al. The preva- lence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data [ J ]. Dis Esop Hagus, 2010,23(6) :451-457.
5Westhoff B, Brotze S, Weston A, et al. The frequency of Barrett's esophagus in high-risk patients with chronic GERD [ J ]. Gastrointest Endosc, 2005,61 ( 2 ) : 226-231.
6Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarci- noma of the gastroesophageal junction [ J ]. World J Surg, 2003,27 ( 9 ) : 999 - 1008.
7Pohl H, Welch H G. The role of overdiagnosis and reclas- sification in the marked increase of esophageal adenocarci- noma incidence [ J ]. J Natl Cancer Inst, 2005,97 (2) : 142- 146.
8Lagergren J, Nandurkar S, Talley N, et al. Gastroesopha- geal reflux with symptom: a dangerous factor of esophageal adenocacinoma [ J ]. N Engl J Med, 1999,340 ( 11 ) : 825- 831.
9Colleypriest B J, Palmer R M, Ward S G, et al. Cdx genes, inflammation and the pathogenesis of Barrett's meta- plasia [ J ]. Trends Mol Med, 2009,15 ( 7 ) : 313-322.
10Clement G, Jablons D M, Benhattar L Targeting the Wnt signaling pathway to treat Barrett's esophagus [ J ]. Expert Opin Ther Targets, 2007,11 (3) :375-389.
